London: British pharmaceutical giant AstraZeneca announced Tuesday that it has begun moving some of its European production to the United States, ahead of President Donald Trump's possible tariffs ...

A new commercial for AstraZeneca’s Truqap constructs a vision of the extra time that the AKT inhibitor can unlock for some breast cancer patients. Truqap was approved by the FDA in late 2023 to ...

AstraZeneca has taken a key step in advancing Breztri Aerosphere toward a potential label expansion and achieving its goal of annual sales of $3 billion to $5 billion for the 3-in-1 inhaler.

Rare Disease Revenue: $2 billion, stable year-on-year. AstraZeneca PLC (NASDAQ:AZN) reported a strong start to 2025 with a 10% increase in total revenue, driven by demand for innovative medicines.

AstraZeneca and health-tech company Qure.ai have completed the risk assessment of 5 million artificial intelligence (AI)-enabled chest X-rays (CXRs) across more than 20 countries in Asia, the ...

AstraZeneca is a posterchild of the UK stock market as Britain's largest listed company. So it's telling that it too is warning that there is a risk a trade war could damage both its bottom line ...

(Alliance News) - AstraZeneca PLC on Friday reported that its triple-combination asthma treatment Breztri Aerosphere met all primary endpoints in two late-stage clinical trials, raising the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Astrazeneca's boss has warned Europe is falling behind as it steps up investment in the United States. Pascal Soriot said innovation in pharmaceuticals ‘has mostly been funded by the US’ as he ...

A fixed-duration regimen of AstraZeneca’s Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, has been recommended for approval in the European Union (EU) for the ...

AstraZeneca has agreed to acquire Belgian in vivo cell therapy biotech EsoBiotec, strengthening its position in the emerging field of treatments that can reprogramme immune cells inside patients ...

AstraZeneca’s biologics division MedImmune is to spin out a new standalone biotech to develop six early-stage inflammation and autoimmunity programmes. To be known as Viela Bio, the spin-out ...